DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 1 – 20 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1 – 20 of copending Application No. 18/820,837 (reference application) and claims 1 – 20 of copending Application No. 18/820,824 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because the claims of the present application and the claims of the ‘824 and ‘837 applications all recite a method apparatus that includes monitoring or receiving information on respiratory depression, presenting an opioid user with a challenge based on the monitoring, and initiating injection of an opioid antidote if the challenge is not successfully met.
This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented.
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.
Claim(s) 1 – 20 is/are rejected under 35 U.S.C. 103 as being unpatentable over Rosinko et al. (US PBPUB 2022/0305202) in view of Ahmed et al. (US PGPUB 2021/0290184).
Regarding claims 1, 10 – 12, and 17, Rosinko discloses a method of detecting and treating in a patient for use in a wearable (e.g. ABSTRACT, ¶ 124, 129, 182), the method comprising:
monitoring the opioid user for respiratory depression utilizing at least one sensor and determining a risk level based on said monitoring (e.g. ¶ 697);
if the risk level determined exceeds a threshold, presenting the opioid user with a challenge (e.g. ¶ 690);
continuing to present the opioid user with the challenge while the risk level is determined to exceed the threshold when the challenge is successfully met (e.g. ¶ 690);
initiating injection of the opioid antidote if it is determined that it is necessary (i.e. the challenge is not successfully met) (e.g. ¶ 807); and
providing a periodic external stimulus to the opioid user after injection of the opioid antidote, said stimulus cancellable thereby (e.g. ¶ 351, 690).
Rosinko fails to teach treating an opioid overdoes in an opioid user, rather treating diabetes. However, Ahmed teaches it is known to treat an opioid overdose in an opioid user using a wearable (e.g. ¶ 60), to present the user with a challenge (e.g. ¶ 277); and to initiate injection of an opioid antidote if it is determined it is necessary (e.g. ¶ 175, 181). It would have been obvious to one having ordinary skill in the art to modify the method as taught by Rosinko with treating an opioid overdose in an opioid user as taught by Ahmed, since such a modification would provide the predictable results of using known method to treat a larger population of patients and presenting quick and efficient treatment in an emergency.
Regarding claim 2, Rosinko discloses said at least one sensor comprises at least one of a pulse oximeter sensor, end tidal CO2 sensor, chest wall muscle monitor, capnography, contactless respiratory rate monitor, body temperature monitor, infrared sensor, heart rate monitor, blood pressure monitor, motion sensor, radar based sensor, optical based sensor, acoustic sensor, thermal based sensor, a respiration monitor belt, and a respiratory sensor (e.g. ¶ 237).
Regarding claim 3, Rosinko discloses the step of monitoring, as described above. Ahmed teaches it is known to obtain pulse oximetry information from a pulse oximetry sensor in contact with the user (e.g. ¶ 45). It would have been obvious to one having ordinary skill in the art to modify the monitoring as taught by Rosinko with the obtaining pulse oximetry information as taught by Ahmed, since such a modification would provide the predictable results of effectively determining if a user is having an overdose using a noninvasive and readily available known sensor.
Regarding claims 4, 5, 13, and 18, Rosinko discloses the challenge comprises having the user complete a task on the wearable or a smartphone (e.g. ¶ 141-142), but doesn’t explicitly state the task comprises solving a puzzle, playing a game, pressing a hard key connected to the wearable, pressing a switch connected to the wearable, or pressing a virtual button on the wearable or a mobile station of the opioid user. Ahmed teaches it is known to use a mobile device and require the user to at least press a virtual button on the wearable or a mobile station (e.g. Figs. 24A, 30 and corresponding text). It would have been obvious to one having ordinary skill in the art to modify the method as taught by Rosinko with requiring the user to press a button as taught by Ahmed, since such a modification would provide the predictable results of providing a simple task that anyone with knowledge of a mobile device could perform.
Regarding claim 6, 14, and 19, Rosinko discloses the invention as discussed above, but does not teach that the opioid antidote comprises naloxone, Narcan, naltrexone, nalmefene, buprenorphine, or an opioid antagonist or mixtures thereof. Ahmed teaches it is known to use an opioid antidote that comprises naloxone, Narcan, naltrexone, nalmefene, buprenorphine, or an opioid antagonist or mixtures thereof (e.g. ¶ 173). It would have been obvious to one having ordinary skill in the art to modify the method as taught by Rosinko with treating an opioid overdose in an opioid user as taught by Ahmed, since such a modification would provide the predictable results of using known method to treat a larger population of patients and presenting quick and efficient treatment in an emergency.
Regarding claim 7, Rosinko discloses the risk level is adapted to indicate that respiratory depression in the user may be imminent (e.g. ¶ 697).
Regarding claims 8, 15, and 20, Rosinko discloses transmitting information related to at least one of the determined risk level, user medical history, overdose status, and injection status of the opioid antidote to a mobile station of a monitor caregiver (e.g. ¶ 878).
Regarding claims 9 and 16, Rosinko discloses requesting pre-authorization for an injection of an opioid antidote from the opioid user and/or a monitor caregiver before opioid use by the opioid user (e.g. ¶ 897).
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to JOSEPH M DIETRICH whose telephone number is (571)270-1895. The examiner can normally be reached Mon - Fri 8:00-5:00.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jennifer McDonald can be reached at 571-270-3061. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/JOSEPH M DIETRICH/Primary Examiner, Art Unit 3796